Alvotech

Alvotech has named a new chief strategy officer, announcing its appointment of Balaji Prasad to the role at the same time as the firm laid out plans for a major acceleration in biosimilars developmen

Alvotech is aiming to have the largest pipeline of any biosimilars developer, after announcing a major ramp-up in development that will see the firm more than quadruple the rate at which it kicks off

Just ahead of Alvotech publishing its annual results, the biosimilars developer has revealed a first filing for its AVT23 proposed biosimilar to Xolair (omalizumab). In conjunction with partner Advanz

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Eyenovia, Betaliq Will Have Combined C